AngioDynamics Inc (ANGO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AngioDynamics Inc (ANGO) has a cash flow conversion efficiency ratio of 0.102x as of May 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($17.45 Million) by net assets ($170.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AngioDynamics Inc (ANGO) total market value for the company's overall valuation and market capitalisation.
AngioDynamics Inc - Cash Flow Conversion Efficiency Trend (2002–2026)
This chart illustrates how AngioDynamics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AngioDynamics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AngioDynamics Inc ranked by their cash flow conversion efficiency. Explore ANGO cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Trend International Logis-Tech Co Ltd
SHE:300532
|
0.073x |
|
General Interface Solution GIS Holding Ltd
TW:6456
|
0.052x |
|
JBG SMITH Properties
NYSE:JBGS
|
0.002x |
|
eXp World Holdings, Inc.
NASDAQ:AGNT
|
0.138x |
|
Turaco Gold Ltd
AU:TCG
|
-0.146x |
|
M Grass Ecology and Environment Group Co Ltd
SHE:300355
|
0.123x |
|
Rashtriya Chemicals and Fertilizers Limited
NSE:RCF
|
0.253x |
|
ZheJiang RIFA Digital Precision Machinery Co Ltd
SHE:002520
|
0.336x |
Annual Cash Flow Conversion Efficiency for AngioDynamics Inc (2002–2026)
The table below shows the annual cash flow conversion efficiency of AngioDynamics Inc from 2002 to 2026. View AngioDynamics Inc (ANGO) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-05-31 | $170.82 Million | $3.09 Million | 0.018x | +132.67% |
| 2025-05-31 | $182.97 Million | $-10.13 Million | -0.055x | +59.59% |
| 2024-05-31 | $205.59 Million | $-28.16 Million | -0.137x | -66527.12% |
| 2023-05-31 | $378.30 Million | $78.00K | 0.000x | +101.22% |
| 2022-05-31 | $424.49 Million | $-7.19 Million | -0.017x | -130.91% |
| 2021-05-31 | $439.46 Million | $24.09 Million | 0.055x | +271.73% |
| 2020-05-31 | $455.87 Million | $-14.55 Million | -0.032x | -152.43% |
| 2019-05-31 | $614.82 Million | $37.44 Million | 0.061x | -19.97% |
| 2018-05-31 | $542.60 Million | $41.29 Million | 0.076x | -29.43% |
| 2017-05-31 | $517.03 Million | $55.74 Million | 0.108x | +20.90% |
| 2016-05-31 | $507.03 Million | $45.22 Million | 0.089x | +89.23% |
| 2015-05-31 | $545.02 Million | $25.68 Million | 0.047x | +2.71% |
| 2014-05-31 | $537.89 Million | $24.68 Million | 0.046x | -9.30% |
| 2013-05-31 | $526.83 Million | $26.65 Million | 0.051x | +128.22% |
| 2012-05-31 | $523.39 Million | $11.60 Million | 0.022x | -73.44% |
| 2011-05-31 | $405.75 Million | $33.87 Million | 0.083x | -18.25% |
| 2010-05-31 | $391.35 Million | $39.96 Million | 0.102x | +90.57% |
| 2009-05-31 | $372.19 Million | $19.94 Million | 0.054x | -26.43% |
| 2008-05-31 | $355.71 Million | $25.91 Million | 0.073x | +178.55% |
| 2007-05-31 | $335.96 Million | $8.78 Million | 0.026x | +0.26% |
| 2006-05-31 | $123.44 Million | $3.22 Million | 0.026x | -73.25% |
| 2005-05-31 | $49.11 Million | $4.79 Million | 0.097x | +45.20% |
| 2004-05-31 | $37.23 Million | $2.50 Million | 0.067x | -85.31% |
| 2003-05-31 | $1.49 Million | $680.00K | 0.457x | +111.18% |
| 2002-05-31 | $-295.00K | $1.21 Million | -4.088x | -- |
About AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vesse… Read more